A Multicenter Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LBL-007 in Combination With Toripalimab in the Treatment of Advanced Malignancies
Latest Information Update: 20 Aug 2024
At a glance
- Drugs LBL-007 (Primary) ; Toripalimab (Primary)
- Indications Head and neck cancer; Nasopharyngeal cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Leads Biolabs
- 16 Aug 2024 Planned End Date changed from 14 Dec 2024 to 14 Mar 2025.
- 16 Aug 2024 Planned primary completion date changed from 1 Jul 2024 to 1 Dec 2024.
- 10 Apr 2024 Preliminary results (by December 1, 2023, n=80 ) assessing safety and efficacy of LBL-007 in combination with toripalimab, in patients with advanced malignant tumors presented at the 115th Annual Meeting of the American Association for Cancer Research